Daiwa Securities Group Inc. Acquires 28,895 Shares of Pfizer Inc. $PFE

Daiwa Securities Group Inc. boosted its holdings in Pfizer Inc. (NYSE:PFE) by 3.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 919,171 shares of the biopharmaceutical company’s stock after purchasing an additional 28,895 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Pfizer were worth $22,887,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Sittner & Nelson LLC boosted its stake in Pfizer by 2.8% in the 4th quarter. Sittner & Nelson LLC now owns 39,007 shares of the biopharmaceutical company’s stock worth $1,062,000 after purchasing an additional 1,045 shares during the period. Verus Capital Partners LLC boosted its stake in Pfizer by 15.3% in the 4th quarter. Verus Capital Partners LLC now owns 23,016 shares of the biopharmaceutical company’s stock worth $573,000 after purchasing an additional 3,057 shares during the period. State of Wyoming boosted its stake in Pfizer by 64.2% in the 4th quarter. State of Wyoming now owns 13,379 shares of the biopharmaceutical company’s stock worth $333,000 after purchasing an additional 5,229 shares during the period. TD Asset Management Inc boosted its position in shares of Pfizer by 6.7% during the 4th quarter. TD Asset Management Inc now owns 3,895,625 shares of the biopharmaceutical company’s stock valued at $97,001,000 after acquiring an additional 245,988 shares during the last quarter. Finally, Lido Advisors LLC boosted its position in shares of Pfizer by 1.5% during the 4th quarter. Lido Advisors LLC now owns 449,675 shares of the biopharmaceutical company’s stock valued at $11,381,000 after acquiring an additional 6,759 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

PFE has been the subject of a number of research reports. Royal Bank Of Canada reiterated an “underperform” rating and set a $25.00 target price on shares of Pfizer in a research report on Monday, April 20th. Morgan Stanley increased their target price on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. Bank of America lowered their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, HSBC increased their target price on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eleven have given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $28.82.

Pfizer Stock Performance

PFE stock opened at $26.04 on Friday. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The business’s fifty day simple moving average is $26.62 and its two-hundred day simple moving average is $26.29. Pfizer Inc. has a twelve month low of $23.11 and a twelve month high of $28.75. The firm has a market cap of $148.43 billion, a price-to-earnings ratio of 19.88 and a beta of 0.34.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. During the same quarter last year, the firm posted $0.92 earnings per share. The business’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be paid a $0.43 dividend. The ex-dividend date is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer signed a license agreement with Chai Discovery to gain early access to its AI drug-discovery platform, including the new Chai-3 model, which could improve antibody design and speed up research productivity. Pfizer signs licence agreement with Chai for AI drug discovery
• Positive Sentiment: Pfizer also reported fresh clinical-trial progress across its oncology pipeline, including updates on a lung cancer study, a bladder cancer combination trial with Astellas, and another advanced lung cancer combination program, signaling continued investment in future growth drivers. Pfizer’s New Lung Cancer Study Signals Fresh Oncology Upside for PFE Investors
• Positive Sentiment: Pfizer disclosed an update on a Phase 3 infant pneumococcal vaccine trial, suggesting continued momentum in its vaccine franchise and potential additional data catalysts ahead. Pfizer’s New Infant Pneumococcal Vaccine Trial: What Investors Should Watch
• Neutral Sentiment: Pfizer’s recent conference presentation and multiple earnings-related recap articles did not introduce a major new financial surprise, but they kept attention on post-earnings expectations and the company’s valuation. Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 Transcript
• Negative Sentiment: Some market commentary continues to highlight that PFE has been under pressure since its last earnings report, reflecting investor caution around near-term growth and execution. Why Is Pfizer (PFE) Down 4.5% Since Last Earnings Report?

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.